Suven Life Sciences, a biopharmaceutical and contract research and manufacturing company has granted an exclusive license and right to distribute and market its Malathion Lotion USP 0.5 per cent w/v with US Patent # 8,138,366 and ANDA 091559 in the US, Canada and Mexico to Taro Pharmaceuticals North America, a subsidiary of Taro Pharmaceutical Industries.
Malathion lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair. Taro will pay Suven a royalty and the arrangement is effective until April 2028 unless otherwise terminated.
EP News Bureau – Mumbai
